| This presentation will provide an overview of the recent advances in metabolic-dysfunction associated steatotic liver disease (MASLD) therapy focused on breakthroughs in pharmacological treatment. The mechanism of actions of promising new drugs for the treatment of metabolic-dysfunction associated steatohepatitis (MASH) with anti-inflammatory, anti-fibrotic, or insulin-sensitizing properties along with their efficacy and safety data from Phase 2 and 3 clinical trials will be shown. This will include a discussion of the first drug approved by the United States Food and Drug Administration for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis, the oral, liver-directed, thyroid hormone receptor beta-selective agonist resmetirom. |
